Fosamax and Osteonecrosis of the Jaw: Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Communication

The legacy of general health and science information dissemination has long served as a foundation for public awareness, covering a broad spectrum of topics from infectious disease outbreaks to chronic condition management. Within this heritage, the communication of pharmaceutical benefits and risks has been a consistent thread, enabling informed decision-making by both clinicians and patients. As the scope of health information has expanded, particular attention has turned to the long-term safety profiles of widely prescribed medications. This evolution naturally leads to a more focused examination of specific adverse events that may arise in distinct patient populations. In the context of mass production and widespread drug utilization, the transition from general health education to occupational exposure concern becomes pertinent. While initial health guidance centered on therapeutic use and patient counseling, the manufacturing and distribution environments introduce unique considerations. Workers involved in the production chain may encounter substances at higher concentrations or through different routes than end-users. This shift in perspective requires a reassessment of risk communication frameworks, moving from population-level advisories to workplace-specific precautions. The following discussion addresses how such a pivot applies to the case of bisphosphonate exposure and associated oral health complications, without delving into mechanistic pathways.

Bridging to Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibition of bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed necrotic bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and non-healing extraction sockets. Diagnosis is based on clinical examination and imaging, with a focus on identifying exposed bone persisting for more than eight weeks in the absence of radiation therapy or metastatic disease. The condition is distinct from other jaw pathologies due to its association with antiresorptive therapy.

Mechanistic Evidence and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current understanding involves the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate suppress bone turnover, which may impair the jawbone's ability to remodel and repair microdamage, particularly after dental procedures. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that the unique structure and vascularity of the jawbone may render it more susceptible to the effects of suppressed bone turnover. Additionally, concomitant factors such as poor oral hygiene, periodontal disease, ill-fitting dentures, and invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery) are known risk factors that can precipitate ONJ in patients taking bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may also increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (Section 5.4). This warning notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors such as invasive dental procedures, cancer diagnosis, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the warning does not specify a precise timeline for risk, and the optimal duration of use for osteoporosis treatment has not been determined, with consideration for drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and ONJ development. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link, as symptoms often resolve upon discontinuation and recur upon re-exposure.

Epidemiological Data and Clinical Implications

The timeline between exposure and documented harm is further clarified by epidemiological data. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the absolute risk is small, the relative risk increases substantially with longer exposure duration. For patients who develop ONJ, the condition can be debilitating, requiring surgical debridement, antibiotic therapy, and discontinuation of bisphosphonate treatment. The risk is particularly elevated in those with additional risk factors such as cancer, corticosteroid use, or poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, the medical literature establishes a clear association between Fosamax use and osteonecrosis of the jaw, supported by mechanistic plausibility, clinical reports, and epidemiological data. The prescribing information includes warnings about this risk, but the absolute risk remains low in osteoporosis patients. For affected individuals, causation considerations include the temporal relationship between drug initiation and ONJ onset, the presence of known risk factors, and the response to drug discontinuation. Clinicians should weigh the benefits of fracture reduction against the rare but serious risk of ONJ, particularly in patients with prolonged exposure or undergoing invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication approved for osteoporosis and Paget's disease. It works by inhibiting bone resorption, which increases bone mass and reduces fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition of exposed necrotic bone in the jaw, often associated with dental procedures. Fosamax use can increase the risk due to suppressed bone turnover, with risk factors including invasive dental work, poor oral hygiene, and prolonged exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How common is ONJ in Fosamax users?

Absolute risk is low, about 0.05% after 5 years, but relative risk increases with duration: threefold after 2-3 years and eightfold after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What should I do if I develop jaw symptoms while taking Fosamax?

Consult your healthcare provider immediately. Symptoms like pain, swelling, or non-healing extraction sockets may indicate ONJ. Discontinuation of bisphosphonate may reduce risk, and treatment may involve surgery and antibiotics.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.